AnaptysBio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANAB research report →
Range $70 – $95
Price Chart
About the company
AnaptysBio, Inc. , a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
- CEO
- Daniel Faga
- IPO
- 2017
- Employees
- 104
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on ANAB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.39B
- P/E
- 7.40
- Fwd P/E
- 10.33
- PEG
- -0.00
- P/S
- 7.30
- P/B
- 67.46
- EV/EBITDA
- 16.62
- Div Yield
- 0.00%
- Gross Margin
- 150.64%
- Op Margin
- 34.62%
- Net Margin
- 96.30%
- ROE
- 906.99%
- ROIC
- -1014.49%
Latest fiscal year · YoY change
- Revenue
- $234.60M+157.0%
- Gross Profit
- $232.18M+420.0%
- Op Income
- $47.90M
- Net Income
- $-13,232,000+90.9%
- EPS
- $-0.46+91.0%
- OCF Growth
- +114.6%
- FCF Growth
- +114.5%
- 52W High
- $72.36
- 52W Low
- $22.07
- 50D MA
- $49.02
- 200D MA
- $51.47
- Beta
- 0.51
- RSI (14)
- 46
- Avg Volume
- 495.13K
No earnings-call transcripts are available for ANAB yet.
- Free Float
- 93.4%
- Shares Outstanding
- 29.73M
- Float Shares
- 27.76M
of shares held by institutions
222 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ecor1 Capital, LLC | 7.88M | 0 |
| Blackrock, Inc. | 1.89M | ▲ 47.46K |
| Vanguard Group Inc | 1.54M | ▲ 67.05K |
| Tang Capital Management LLC | 1.47M | ▲ 143.38K |
| State Street Corp | 1.15M | ▼ 140.29K |
| Vanguard Capital Management LLC | 909.95K | ▲ 3.71K |
| Goldman Sachs Group Inc | 850.34K | ▲ 266.27K |
| Sanofi | 821.92K | 0 |
| D. E. Shaw & Co., Inc. | 819.59K | ▲ 279.93K |
| Millennium Management LLC | 784.56K | ▼ 22.76K |
| 683 Capital Management, LLC | 740.00K | ▲ 80.00K |
| Citadel Advisors LLC | 650.59K | ▲ 256.21K |
Held by 279 ETFs
Biggest fund positions in ANAB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | EcoR1 Capital, LLC | buy | 138,093 |
| Nov 17, 26 | EcoR1 Capital, LLC | buy | 152,367 |
| Nov 16, 26 | EcoR1 Capital, LLC | buy | 84,120 |
| Oct 1, 26 | RENTON HOLLINGS | other | 5,000 |
| Oct 1, 26 | RENTON HOLLINGS | sell | 5,000 |
| Oct 1, 26 | RENTON HOLLINGS | other | 5,000 |
| Sep 15, 26 | Orwin John A | other | 1,300 |
| Sep 15, 26 | Orwin John A | other | 1,300 |
| Mar 12, 26 | Lizzul Paul F. | other | 16,667 |
| Mar 12, 26 | Faga Daniel | other | 53,334 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANAB coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ANAB?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
3 Stocks With Superb Earnings Acceleration to Buy Before 2027
zacks.com · Nov 19
AnaptysBio, Inc. (ANAB) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
AnaptysBio, Inc. (ANAB) Misses Q3 Earnings and Revenue Estimates
zacks.com · Nov 12
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
globenewswire.com · Nov 12
Anaptys Announces Participation in Upcoming Investor Conferences
globenewswire.com · Nov 10
Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity
seekingalpha.com · Oct 30
Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors
seekingalpha.com · Oct 29
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
zacks.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
